Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
PARP inhibitor
carbon ion radiotherapy
chromothripsis
medulloblastoma
synthetic lethality
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
29
5
2021
medline:
20
1
2022
entrez:
28
5
2021
Statut:
ppublish
Résumé
Medulloblastomas with chromothripsis developing in children with Li-Fraumeni Syndrome (germline TP53 mutations) are highly aggressive brain tumors with dismal prognosis. Conventional photon radiotherapy and DNA-damaging chemotherapy are not successful for these patients and raise the risk of secondary malignancies. We hypothesized that the pronounced homologous recombination deficiency in these tumors might offer vulnerabilities that can be therapeutically utilized in combination with high linear energy transfer carbon ion radiotherapy. We tested high-precision particle therapy with carbon ions and protons as well as topotecan with or without PARP inhibitor in orthotopic primary and matched relapsed patient-derived xenograft models. Tumor and normal tissue underwent longitudinal morphological MRI, cellular (markers of neurogenesis and DNA damage-repair), and molecular characterization (whole-genome sequencing). In the primary medulloblastoma model, carbon ions led to complete response in 79% of animals irrespective of PARP inhibitor within a follow-up period of 300 days postirradiation, as detected by MRI and histology. No sign of neurologic symptoms, impairment of neurogenesis or in-field carcinogenesis was detected in repair-deficient host mice. PARP inhibitors further enhanced the effect of proton irradiation. In the postradiotherapy relapsed tumor model, median survival was significantly increased after carbon ions (96 days) versus control (43 days, P < .0001). No major change in the clonal composition was detected in the relapsed model. The high efficacy and favorable toxicity profile of carbon ions warrants further investigation in primary medulloblastomas with chromothripsis. Postradiotherapy relapsed medulloblastomas exhibit relative resistance compared to treatment-naïve tumors, calling for exploration of multimodal strategies.
Sections du résumé
BACKGROUND
Medulloblastomas with chromothripsis developing in children with Li-Fraumeni Syndrome (germline TP53 mutations) are highly aggressive brain tumors with dismal prognosis. Conventional photon radiotherapy and DNA-damaging chemotherapy are not successful for these patients and raise the risk of secondary malignancies. We hypothesized that the pronounced homologous recombination deficiency in these tumors might offer vulnerabilities that can be therapeutically utilized in combination with high linear energy transfer carbon ion radiotherapy.
METHODS
We tested high-precision particle therapy with carbon ions and protons as well as topotecan with or without PARP inhibitor in orthotopic primary and matched relapsed patient-derived xenograft models. Tumor and normal tissue underwent longitudinal morphological MRI, cellular (markers of neurogenesis and DNA damage-repair), and molecular characterization (whole-genome sequencing).
RESULTS
In the primary medulloblastoma model, carbon ions led to complete response in 79% of animals irrespective of PARP inhibitor within a follow-up period of 300 days postirradiation, as detected by MRI and histology. No sign of neurologic symptoms, impairment of neurogenesis or in-field carcinogenesis was detected in repair-deficient host mice. PARP inhibitors further enhanced the effect of proton irradiation. In the postradiotherapy relapsed tumor model, median survival was significantly increased after carbon ions (96 days) versus control (43 days, P < .0001). No major change in the clonal composition was detected in the relapsed model.
CONCLUSION
The high efficacy and favorable toxicity profile of carbon ions warrants further investigation in primary medulloblastomas with chromothripsis. Postradiotherapy relapsed medulloblastomas exhibit relative resistance compared to treatment-naïve tumors, calling for exploration of multimodal strategies.
Identifiants
pubmed: 34049392
pii: 6287957
doi: 10.1093/neuonc/noab127
pmc: PMC8643436
doi:
Substances chimiques
Carbon
7440-44-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2028-2041Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
Nat Commun. 2018 Nov 12;9(1):4760
pubmed: 30420702
Nat Genet. 2016 Mar;48(3):238-244
pubmed: 26780609
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674721
Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1):
pubmed: 30709875
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Clin Cancer Res. 2007 May 15;13(10):3033-42
pubmed: 17505006
Gynecol Oncol. 2020 Feb;156(2):488-497
pubmed: 31630846
Nat Med. 2018 Nov;24(11):1752-1761
pubmed: 30349086
Clin Cancer Res. 2019 Jul 1;25(13):3759-3771
pubmed: 30760478
Neoplasia. 2020 Sep;22(9):431-440
pubmed: 32652442
Semin Radiat Oncol. 2006 Oct;16(4):249-59
pubmed: 17010908
Acta Oncol. 2013 Oct;52(7):1504-9
pubmed: 23962241
Oncogene. 2003 Sep 1;22(37):5784-91
pubmed: 12947386
Clin Cancer Res. 2007 May 1;13(9):2728-37
pubmed: 17473206
JAMA Oncol. 2016 Dec 1;2(12):1539-1540
pubmed: 27541302
Nature. 2014 Apr 3;508(7494):98-102
pubmed: 24670643
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Cancer Res. 2014 Dec 1;74(23):7137-48
pubmed: 25304265
Front Oncol. 2019 May 14;9:391
pubmed: 31139573
Radiat Oncol. 2012 Oct 17;7:170
pubmed: 23072718
Radiat Res. 2020 Feb;193(2):186-194
pubmed: 31774721
Neoplasia. 2014 May;16(5):432-40
pubmed: 24970386
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Lancet Oncol. 2019 May;20(5):674-685
pubmed: 30885458
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Mol Cancer Ther. 2018 Apr;17(4):858-868
pubmed: 29437879
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cancer Med. 2020 Nov;9(21):7954-7963
pubmed: 32931654
Mutat Res Rev Mutat Res. 2018 Jul - Sep;777:29-51
pubmed: 30115429
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
Int J Cancer. 2016 May 15;138(10):2322-33
pubmed: 26455580
Nat Rev Drug Discov. 2011 May;10(5):351-64
pubmed: 21532565
Cancer. 2009 Mar 15;115(6):1348-55
pubmed: 19156905
Cancers (Basel). 2017 Jun 09;9(6):
pubmed: 28598362
Nature. 2018 Jul;559(7714):E10
pubmed: 29875405
Cell. 2019 Jun 13;177(7):1842-1857.e21
pubmed: 31155235
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Curr Opin Oncol. 2014 Jan;26(1):64-72
pubmed: 24305569
Clin Cancer Res. 2018 Feb 15;24(4):744-752
pubmed: 29138343
Clin Cancer Res. 2009 Jan 15;15(2):607-12
pubmed: 19147766
Invest New Drugs. 2013 Aug;31(4):949-58
pubmed: 23315029
Cell. 2012 Jan 20;148(1-2):59-71
pubmed: 22265402
Trends Pharmacol Sci. 2010 Aug;31(8):372-80
pubmed: 20598756
Oncotarget. 2018 May 1;9(33):22976-22985
pubmed: 29796166
BMC Cancer. 2010 Mar 12;10:96
pubmed: 20226028